Milestone Pharmaceuticals/MIST

$1.72

-1.43%
-
1D1W1MYTD1YMAX

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Ticker

MIST

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Oliveto

Employees

47

Headquarters

Montreal, Canada

MIST Metrics

BasicAdvanced
$92M
Market cap
-
P/E ratio
-$1.25
EPS
1.76
Beta
-
Dividend rate
$92M
1.76097
$4.39
$1.33
329K
22.752
126.861
126.861
-53.21%
-117.39%
-56.51%
2.321
2.317
-100%
10.49%

What the Analysts think about MIST

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
495.93% upside
High $25.00
Low $2.00
$1.72
Current price
$10.25
Average price target

MIST Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$10M
-24.26%
Profit margin
0%
NaN%

MIST Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.23%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.35
-$0.32
-$0.21
-
Expected
-$0.39
-$0.38
-$0.31
-$0.26
-$0.19
Surprise
-4.15%
-8.38%
2.4%
-19.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Milestone Pharmaceuticals stock?

Milestone Pharmaceuticals (MIST) has a market cap of $92M as of May 22, 2024.

What is the P/E ratio for Milestone Pharmaceuticals stock?

The price to earnings (P/E) ratio for Milestone Pharmaceuticals (MIST) stock is 0 as of May 22, 2024.

Does Milestone Pharmaceuticals stock pay dividends?

No, Milestone Pharmaceuticals (MIST) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Milestone Pharmaceuticals dividend payment date?

Milestone Pharmaceuticals (MIST) stock does not pay dividends to its shareholders.

What is the beta indicator for Milestone Pharmaceuticals?

Milestone Pharmaceuticals (MIST) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Milestone Pharmaceuticals stock price target?

The target price for Milestone Pharmaceuticals (MIST) stock is $10.25, which is 495.93% above the current price of $1.72. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Milestone Pharmaceuticals stock

Buy or sell Milestone Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing